Skip to main content

Primary Biliary Cholangitis clinical trials at University of California Health

6 in progress, 5 open to eligible people

Showing trials for
  • A Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    open to eligible people ages 18-75

    The main objective of the study is to evaluate the effect of daily oral administration of 80mg elafibranor on cholestasis (impairment of bile formation and/or bile accumulation) in patients with PBC and inadequate response or intolerance to Ursodeoxycholic Acid (UCDA)

    at UC Davis

  • A Study of Investigational Seladelpar in Primary Biliary Cholangitis (PBC)

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    open to eligible people ages 18-75

    To evaluate the treatment effect of seladelpar on composite biochemical improvement in cholestasis markers based on ALP and total bilirubin and to evaluate the safety of seladelpar over 12 months of treatment compared to placebo

    at UC Davis UCSF

  • A Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC) and Abnormal Liver Function

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    open to eligible people ages 18-80

    The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

    at UC Davis

  • Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

    open to eligible people ages 18-75

    An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

    at UC Davis

  • Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

    open to eligible people ages 18-75

    This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.

    at UC Davis

  • A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

    Sorry, in progress, not accepting new patients

    This is a 5-year, longitudinal, observational study of patients with PBC designed to specifically address important clinical questions that remain incompletely answered from registration trials. In addition to the study database, a bio specimen repository will also be included so that translational studies of genomics and biomarkers of response may be performed.

    at UC Davis

Our lead scientists for Primary Biliary Cholangitis research studies include .

Last updated: